JNJ

Johnson JohnsonB

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

20%

Probability

Target price

$300.00

Analysis reference price unavailable

Analysis 2026-07-20 · RankAlpha Sentiment Codex

Most likely

Base case

55%

Probability

Target price

$275.00

Analysis reference price unavailable

Analysis 2026-07-20 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$225.00

Analysis reference price unavailable

Analysis 2026-07-20 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-07-20

AI commentary

Post-earnings tone is moderately positive but market confirmation is incomplete. JNJ beat adjusted EPS expectations, raised guidance, and received several constructive analyst updates, while shares fell 2.69% on July 15 before rising 1.19% and 1.23% on July 16-17. The mixed initial reaction and limited target-dispersion data support monitoring rather than an aggressive bullish stance. [Johnson & Johnson Q2 2026 results](https://www.investor.jnj.com/investor-news/news-details/2026/Johnson--Johnson-reports-Q2-2026-results-raises-2026-outlook/default.aspx) [JNJ historical prices](https://ca.investing.com/equities/johnson-johnson-historical-data)

RankAlpha Sentiment Codex - 2026-07-20

Open post-earnings memo

Evidence flagged

later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Impact

tentative

Confidence

AI events

2026-07-15eventQ2 results and raised 2026 outlookMedium impact

JNJ reported Q2 sales of $25.31 billion, adjusted EPS of $2.90, and raised 2026 guidance to $101.1 billion reported sales and $11.68 adjusted EPS at the midpoint. Innovative Medicine operational growth was 6.8%, driven by DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, TREMFYA, SPRAVATO, and CAPLYTA, while STELARA reduced growth by approximately 760 basis points. [#SEC-8K-2026-07-15] [SEC Exhibit 99.1](https://www.sec.gov/Archives/edgar/data/200406/000020040626000146/a2026q2exhibit991.htm)

2026-07-16catalystMixed-positive post-print analyst revisionsMedium impact

Guggenheim maintained Buy and a $270 target after the Q2 report; Bernstein raised its target from $251 to $261 while retaining Market Perform, and Freedom Capital upgraded JNJ to Buy with a $280 target from $230. Guggenheim coverage cited adjusted EPS of $2.90 versus a $2.85 consensus estimate. [Guggenheim](https://www.investing.com/news/analyst-ratings/guggenheim-reiterates-johnson--johnson-stock-rating-on-q2-beat-93CH-4795505) [Bernstein](https://www.investing.com/news/analyst-ratings/bernstein-raises-johnson--johnson-stock-price-target-on-earnings-beat-93CH-4796054) [Freedom Capital](https://www.investing.com/news/analyst-ratings/freedom-capital-upgrades-johnson--johnson-stock-rating-on-strong-quarter-93CH-4796593)

2026-12-08eventEnterprise Business Review provides a dated strategic checkpointMedium impact

Management scheduled an Enterprise Business Review for December 8, 2026, creating a dated opportunity to clarify the path toward double-digit growth and portfolio priorities. [#SEC-8K-2026-04-14]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-20 • Updated nightlySource: Internal modelMethodology